The head of Illumina, the world’s largest gene sequencing company, has warned that EU attempts to block its $8 billion acquisition of cancer-test maker Grail will cost lives and have a chilling effect on biotech investment. Arman Oruc, a partner in the antitrust and competition practice at Goodwin, explains that this is happening increasingly more. Read the Financial Times article here.